Home > Sciences De La Vie > Industrie Pharmaceutique > Thérapies > Pipeline Insight: Migraine - ...
AUTRES RESSOURCES
 
AUTRES SECTEURS
 
TOUS NOS SECTEURS
 
Thérapies > Etude de marché sectorielle
 Pipeline Insight: Migraine - Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries
€ 9 120,00
Editeur :
Datamonitor
Langue :
Anglais
Date de publication :
Décembre 2006
Taille du document :
234
Autres informations :
Description , Table des matières
 

Recevez cette publication aujourd'hui !
Plus d'information ?
09 70 463 423
 
Documents Publics
1,200,000 documents
Téléchargement illimités
 
Etudes Privées
50,000 rapports et études
Paiement à la piéce
 
1.Télécharger nos rapports publics

Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...

Nos documents publics sur le même théme (2)
Pharmaceutical industry market in USA and Canada
21 pages | Novembre 2006 | Anglais
 
 
   
Main focus: clinical trial,clinical trials,toxicology,...
Research focus: market outlook,market size and estimates,
Geographic focus: usa,canada,spain
   
Pharmaceutical industry market in China and Japan
21 pages | Octobre 2006 | Anglais
 
 
   
Main focus: clinical trial,pharmaceutical,clinical trials,...,...
Research focus: market size and estimates,economy outlook
Geographic focus: china,japan,india,indonesia,malaysia,singapore,...
   
Autres recherches sur le même thème
Rechercher d'autres rapports publics à télécharger
 
 
 
2. Rechercher d'autres rapports et études à commander

Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux


Rapports privés en relation
Top CNS Portfolios in 2004 - The Industry Gold Standards
57 pages | Janvier 2005 |
IntroductionThe market for central nervous system prescription drugs grew 21.3% to reach $62.4 billion in 2003.
The growth of this massive market is due to companies accessing previously untapped p
1 520,00 €
 
 
Pipeline Insight: Hematological malignancies - Targeted treatments and immunotherapy infuse new blood
219 pages | Avril 2005 |
IntroductionGiven an enhanced understanding of the biological basis for oncogenesis and the benefit of immunotherapy approaches such as Genentech/Roche's Rituxan, it is no surprise that targeted treat
9 120,00 €
 
 
Pipeline Insight: ADHD - Shire Driving Diversity in ADHD
205 pages | Juin 2005 |
IntroductionThe current ADHD market has long been saturated with traditional methylphenidate and amphetamine based drugs, with the only innovations being the development of extended release versions.<
9 120,00 €
 
 
MarketWatch: CNS
25 pages | Janvier 2005 |
Datamonitor's CNS MarketWatch is a one-stop news shop for timepressed executives.
It provides monthly insight into the key events in the CNS industry.
The report contains the latest news, analys
160,00 €
 
 
Stakeholder Insight: Pancreatic Cancer - Gold Standard Gemcitabine Waiting to be Challenged
259 pages | Décembre 2004 |
IntroductionPancreatic adenocarcinoma is the fifth leading cancer-related cause of death and is thus a major health issue in the developed world.
Its aggressive nature and resistance to conventiona
12 160,00 €
 
 
The Cancer Outlook 2000
128 pages | Septembre 2000 |
Driven by the cytotoxic, adjunct and innovative drug classes, the cancer market grew by 16% in 1999 to a global value of almost $19bn, and is now poised on the verge of a period of significant exp
955,00 €
 
 
05-070: The Neuroscience Perspective: Opportunities for Market Entry & Expansion
138 pages | Octobre 2005 |
This report provides suppliers with critical information regarding neuroscientists’ preferred techniques and instrumentation in four strategic areas: nucleic acids, proteins, cells and imaging
2 400,00 €
 
 
MarketWatch: Cancer
31 pages | Janvier 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the
160,00 €
 
 
Nutraceuticals - Targeting Consumers Aged 14 –34
146 pages | Septembre 2000 |
The 14-34 age group represents approximately 30% of the total population across the 8 countries covered in the report, and as such are a key target audience.
This group is particularly critic
955,00 €
 
 
MarketWatch: CNS
30 pages | Avril 2005 |
Datamonitor's CNS MarketWatch is a one-stop news shop for timepressed executives.
It provides monthly insight into the key events in the CNS industry.
The report contains the latest news, analys
160,00 €
 
 
 
Autres secteurs en relation
Rechercher d'autres rapports!
 
 
 
Présentation de l'étude de marché - Description & Table des matières
 Pipeline Insight: Migraine - Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries

Introduction
After the launch of Trexima in 2007, triptan genericization coupled with a weak late-stage pipeline will result in a major shift in market dynamics, and will result in the migraine market value decreasing to $3.2 billion in 2015. The market remains receptive to superior prophylactics however, with innovation being essential for the progression of the acute market, post-triptan era.

Scope
Analysis of patient potential, unmet needs and clinical trial design in migraine
Overview of drugs in preregistration, Phase III, II and I; with analysis of key companies involved in the R&D pipeline
Detailed profiles of key compounds in development for use in migraine, with forecasts of drug revenues to 2015
Discussion of GSK and Pozen's strategies and insight from key industry opinion leaders
Highlights
Due to Imitrex's commercial success, GSK is the current migraine market leader. Trexima, co-developed by GSK and Pozen represents GSK's product line extension for its migraine franchise, but approval delays and the impending US sumatriptan patent expiry will limit its success.

The next big thing in the prophylactic market will be the label expansion of Allergan's Botox and Ipsen's Dysport. Seven major market Botox and Dysport combined sales for migraine are forecast to grow to over $170m in 2015.

The presence of glutamatergic receptor inhibitors, NOS inhibitors and CGRP antagonists, amongst others in early stage clinical trials, indicate companies are developing innovative drugs for the post triptan future. With all identified to play a role in the biological mechanisms of migraine, there holds great potential in such novel drug targets.

Reasons to Purchase
Understand unmet needs in the migraine market based on key opinion leader comments
Benchmark key late-stage migraine compounds against current market leaders
Assess the combined US, Japan, five major EU sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential


 

Pipeline Insight: Migraine - Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries


New Search:

PPLSEN